Home » Topics » Disease categories and therapies » Ocular

Ocular
RSS

Tosufloxacin tosilate eye drops submitted for Japanese approval

June 9, 2004

SnET2 NDA accepted for priority review

June 4, 2004

Proposed financing at InSite to advance AzaSite development

June 4, 2004

Allergan and Kyorin sign Japanese agreement for Alphagan franchise

June 2, 2004

FDA sets date to discuss Macugen NDA

June 1, 2004

Allergan presents new prostaglandin analogues with utility as ocular hypotensive agents

May 28, 2004

NDA filing for Xibrom

May 27, 2004

Allergan and Senju sign Japanese licensing agreement for Lumigan

May 27, 2004

Novel ocular hypotensive agent BVT-28949 effective in monkeys

May 20, 2004

Pharmacokinetics and efficacy of ranibizumab in exudative AMD

May 14, 2004

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...